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ARTICLES
Structural definition of a conserved
neutralization epitope on HIV-1 gp120
Tongqing Zhou1, Ling Xu1, Barna Dey1, Ann J. Hessell3, Donald Van Ryk2, Shi-Hua Xiang4, Xinzhen Yang4,
Mei-Yun Zhang5, Michael B. Zwick3, James Arthos2, Dennis R. Burton3, Dimiter S. Dimitrov5, Joseph Sodroski4,
Richard Wyatt1, Gary J. Nabel1 & Peter D. Kwong1
The remarkable diversity, glycosylation and conformational flexibility of the human immunodeficiency virus type 1 (HIV-1)
envelope (Env), including substantial rearrangement of the gp120 glycoprotein upon binding the CD4 receptor, allow it to
evade antibody-mediated neutralization. Despite this complexity, the HIV-1 Env must retain conserved determinants that
mediate CD4 binding. To evaluate how these determinantsmight provide opportunities for antibody recognition, we created
variants of gp120 stabilized in the CD4-bound state, assessed binding of CD4 and of receptor-binding-site antibodies, and
determined the structure at 2.3 A˚ resolution of the broadly neutralizing antibody b12 in complex with gp120. b12 binds to a
conformationally invariant surface that overlaps a distinct subset of the CD4-binding site. This surface is involved in the
metastable attachment of CD4, before the gp120 rearrangement required for stable engagement. A site of vulnerability,
related to a functional requirement for efficient association with CD4, can therefore be targeted by antibody to neutralize
HIV-1.
The human immunodeficiency virus type 1 (HIV-1) crossed from
chimpanzees to humans early in the twentieth century and has since
infected,1% of the world’s adult population1,2. This spread and the
absence of an effective vaccine are to a large degree a consequence of
the ability of HIV-1 to evade antibody-mediated neutralization3–5.
On HIV-1, the only viral target available for neutralizing antibodies is
the envelope spike, which is composed of three copies of the gp120
exterior envelope glycoprotein and three gp41 transmembrane glyco-
protein molecules6,7. Genetic, immunological and structural studies
of the HIV-1 envelope glycoproteins have revealed extraordinary
diversity, manifest in a variety of immunodominant loops, as well
as multiple overlapping mechanisms of humoral evasion, including
self-masquerading glycan and conformational masking8–11. These
evolutionarily honed barriers of diversity and evasion have confoun-
ded traditional vaccine development.
Two strategies have been proposed to surmount these barriers:
examination of known broadly neutralizing antibodies (2F5, 2G12,
4E10 and b12) to identify susceptible targets of neutralization12, and
analysis of functional constraints to identify potential sites of vulner-
ability13. To facilitate viral entry, the gp120 glycoprotein must bind to
cell-surface CD4 (ref. 14), alter its conformation to reveal a site for
co-receptor attachment15, and trigger conformational rearrange-
ments in the gp41 glycoprotein to mediate fusion of viral and host
cell membranes16,17. Constraints on envelope (Env) variation and
exposure, associated with required functions of viral entry, provide
potential footholds for broad, antibody-mediated neutralization.
Here we combine analysis of function with clues from antibody.
We constructed stabilized gp120 molecules, constrained to stay in the
CD4-bound conformation even in the absence of CD4, and tested the
effect of this stabilization on the binding kinetics of CD4 and on
antibodies reactive with sites of receptor binding. We then deter-
mined the crystal structure of the broadly neutralizing antibody
b12 in complex with one of the stabilized gp120 molecules.
Analysis of this structure, combined with detailed antigenic analyses
of gp120 molecules stabilized to various extents in the CD4-bound
conformation, not only reveals the functionally conserved surface
that allows for initial CD4 attachment, but also provides an
atomic-level description of the b12 epitope, which serves as a key
target for humoral neutralization of HIV-1.
Recognition of the CD4-binding site
Conformational flexibility of HIV-1 gp120 complicated analysis of
antibody recognition. To circumvent this complication, we used an
iterative structure-based scheme to stabilize gp120 in its CD4-bound
state (Table 1, Supplementary Fig. 1 and Supplementary Tables 1
and 2). The CD4-bound state of gp120 comprises an inner domain,
outer domain and four-stranded bridging sheet mini-domain18. Five
disulphides and four cavity-altering substitutions were created to
restrict interdomain movements and to stabilize bridging sheet
formation. Crystallographic analysis of gp120 variants with these
substitutions in complex with CD4 and antibody 17b at 2.0–2.2 A˚
resolution showed that four of five disulphides formed and that
disulphide and cavity-altering substitutions induced minimal struc-
tural perturbation. We also analysed a two-disulphide variant at 2.5 A˚
resolution as well as a three-disulphide variant at 2.8 A˚ resolution
(Table 1). In both structures, all potential disulphides formed.
To measure the degree of conformational fixation, we used iso-
thermal titration calorimetry to assess the entropy of interaction
between the different stabilized gp120 cores and CD4 (Table 1 and
Supplementary Table 3). Disulphides had a more substantial effect
than cavity-altering substitutions. Tethering the centre two strands
of the bridging sheet (by linking residues 123–431) or the termini-
proximal ends of the domains (96–275 or 231–267) reduced the
entropy of interaction by 15–30%. A more substantial effect (a
60% reduction) was gained by tethering the bridging sheet to the
inner domain (109–428). Thermodynamic analysis thus quantified
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the degree of variant gp120 stabilization and demonstrated substan-
tial remaining flexibility, despite the presence of up to three stabil-
izing disulphides.
Because the epitope for CD4-induced antibodies is only formed in
the CD4-bound state10,19,20, we could use the increase in antibody on-
rate to assess the degree to which stabilization ‘preformed’ the variant
gp120 molecules in the CD4-bound state. Reasonable correlations
were observed between the on-rate for CD4-induced antibodies and
the entropy of CD4 binding (r5 0.74, P, 0.036 for antibody 17b
(ref. 19); r5 0.76, P, 0.029 for antibody m6 (ref. 21)), with the most
extreme change for the three-disulphide variant (a 95-fold increase in
on-rate for antibody 17b and a 65-fold increase for antibody m6)
(Table 1 and Supplementary Fig. 1c).
Notably, almost no change in CD4 on-rate was observed with the
stabilized gp120 molecules (Table 1, Supplementary Table 4 and
Supplementary Fig. 1c), suggesting that the initial contact surface
recognized by CD4 is present in unliganded gp120 before the CD4-
induced conformational change. Similarly invariant on-rates have
recently been reported for CD4 binding to gp120 molecules
restrained from achieving a CD4-bound conformation by removing
a flexible loop22. Thus, in contrast to the CD4-induced antibodies, a
conformational change is not required to expose an initial site of
contact for CD4. Rather, it serves to lock CD4 into place once contact
has been made.
To determine the degree to which fixation of gp120 in its CD4-
bound conformation restricts antigenic recognition, we tested bind-
ing of a panel of CD4-binding-site antibodies to the stabilized gp120
variants (Table 1). The average overall difference in free energy of
binding for CD4-binding-site antibodies to wild type and stabilized
variants correlated well with the change in entropy of variant gp120
binding to CD4 (r5 0.89, P, 0.0035) (Supplementary Fig. 1c).
Conformational constraint thus effectively hides the CD4-bound
conformation of gp120 from recognition by antibodies that target
the site of CD4 binding. Indeed, of all the CD4-binding-site antibod-
ies tested, only the unique, broadly neutralizing antibody b12 was
able to bind well to stabilized gp120.
Structure of a b12–gp120 complex
Although gp120 is the primary target of neutralizing antibodies eli-
cited during natural infection23, most gp120-reactive antibodies are
ineffective at neutralizing primary HIV-1 isolates (reviewed in refs 4,
24). Only two gp120-reactive antibodies (b12, 2G12) with effective
neutralization activity against diverse primary HIV-1 isolates have
thus far been identified25–27. In vivo, b12 can protect macaques against
vaginal challenge from pathogenic simian–human immunodefi-
ciency virus (SHIV)28. Although the structure of the entire, unbound
b12 immunoglobulin (IgG1) has been determined29, a molecular
description of its interaction with gp120 remained elusive.
To facilitate a structural understanding of b12 neutralization of
HIV-1, we screened crystallizations of b12 in complex with various
forms of gp120. The lack of b12 conformational fixation of gp120
(ref. 10), coupled to inherent gp120 flexibility, complicated crystal-
lization of a b12–gp120 complex; to overcome this complication, we
Table 1 | Characterization of stabilized gp120 cores.
gp120* Resolution
(A˚)
Entropy of
CD4
interaction
(2TDS)
(kcalmol21)
Ligands
CD4 CD4-induced antibodies CD4-binding-site antibodies
17b m6 b12 b3 b6 b11 b13 m14 m18 F91 F105 15e
On{
(3104)
Kd
(nM)
On{
(3104)
Kd
(nM)
On{
(3104)
Kd
(nM)
Kd(WT)/Kd(mutant)
Wild type (WT) 2.00 39.7 2.5 52 0.69 560 2.2 2,400 1 1 1 1 1 1 1 1 1 1
F2 2.05 39.1 4.7 3.5 2.9 530 14 680 0.28 1.0 4.631025 1.631023 0.73 5.231023 0.29 9.031023 ,1025 ,1025
Ds1 F123 2.20 28.3 3.5 14 3.4 230 12 490 0.43 0.29 1.931025 9.031024 0.95 0.059 0.21 4.231023 ,1025 ,1025
Ds2 F2 2.00 17.2 5.3 4.8 10 200 32 400 0.085 ,1025 ,1025 ,1025 0.029 ,1025 1.531024 ,1025 ,1025 ,1025
Ds3 F2 2.00 26.9 3.8 1.9 9.5 120 25 220 0.42 0.72 3.331025 2.531023 0.67 3.331023 0.28 2.731023 ,1025 ,1025
Ds4 F2 2.00 34.2 4.5 2.8 2.3 820 8.4 2,200 0.30 0.97 0.49 1.631023 0.56 2.431023 0.34 6.231023 ,1025 ,1025
Ds12 F123 2.50 18.5 4.9 10 3.7 320 19 710 0.60 ,1025 ,1025 ,1025 7.631023 ,1025 3.231023 ,1025 ,1025 ,1025
Ds123 F12 2.80 18.7 3.0 1.9 66 19 140 32 1.1 ,1025 ,1025 ,1025 1.631023 ,1025 2.631023 ,1025 ,1025 ,1025
Stabilized gp120 cores were characterized by X-ray crystallography, isothermal titration calorimetry and surface-plasmon resonance. Kd, dissociation constant.
* gp120 core variants as defined by cavity-altering substitutions: F1, M95W; F2, T257S/S375W; F3, A433M; and also by disulphide (Ds)-bond-forming cysteine substitutions: Ds1, W96C/V275C;
Ds2, I109C/Q428C; Ds3, T123C/G431C; Ds4, K231C/E267C.
{On-rate of ligand binding to gp120 (units in M21 s21).
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Figure 1 | Structure of b12 in complex with an HIV-1 gp120 core.
Polypeptide chains are depicted in ribbon representation, with disordered
regions as dashed lines. The gp120 inner domain is grey, and the outer
domain is red, except for the CD4-binding loop, which is purple. The strands
and associated loops, which in the CD4-bound conformation correspond to
the bridging sheet, are blue. The b12 light chain is blue–grey and the b12
heavy chain is green, with associated CDRs highlighted in orange (H1), cyan
(H2) and dark green (H3). The heavy-chain dominance of the binding
interaction is apparent, with the nearest light-chain approach separated by
,10 A˚ from gp120. Heavy-chain-only interactions are rare, although heavy-
chain interactions predominate in a number of viral Env–antibody
complexes, including those from SARS coronavirus49 and influenza virus
haemagglutinin50. Three b12 residues (Asn 31, Tyr 53 and Trp 100) from
each of the heavy-chain CDRs are depicted in stick representation. Together,
these three residues combine to form,40% of the b12 contact surface. They
can be seen gripping the CD4-binding loop, the central focus of the b12
interaction with gp120.
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used the mutationally stabilized gp120 molecules. Complexes with
wild-type core or with single-disulphide variants (96–275 or 123–
431) failed to produce crystals suitable for structural analysis.
However, diffraction to 2.3 A˚ was obtained from hexagonal crystals
of the antigen-binding fragment (Fab) of b12 in complex with a two-
disulphide-stabilized gp120 core. We solved the complex structure
by molecular replacement and refined it to an R-value of 19.3%
(Rfree5 25.5%) (Supplementary Table 5).
Notably, only the heavy chain of b12 interacted with gp120, with
each of the three heavy-chain complementarity-determining regions
(CDRs) making extensive contact (Fig. 1, Supplementary Table 6 and
Supplementary Figs 2 and 3). Despite this unusual heavy-chain-only
usage, the surface areas of interaction were in the range typical for
antibody–protein interfaces (reviewed in ref. 30), with a total of
1,480 A˚2 buried31 in the interaction (737 A˚2 on gp120 and 743 A˚2
on b12).
The gp120 surface bound by b12 was confined largely to the gp120
outer domain, consistent with predictions from alanine substitutions
(Supplementary Table 7 and ref. 32). We examined this surface for
features that might make it amenable to antibody recognition. The
outer domain is composed of two barrels, stacked end to end (Fig. 2).
The termini-distal barrel comprises seven anti-parallel b-strands;
the other contains six b-strands embracing the a2 helix. b12 binds
at the barrel–barrel juncture to the gp120 face opposite the a2 helix.
Although most of the gp120 backbone is involved in secondary struc-
ture interactions, the barrel juncture contains a number of struc-
tural elements with unpaired backbone, often used by antibodies in
recognition. Principal among these are two parallel loops—the CD4-
binding loop and the outer domain exit loop—that extend from the
only two parallel b-strands in the entire gp120 core. b12 takes advant-
age of this backbone reactivity, forming six direct and four water-
mediated hydrogen bonds with the main-chain atoms of these two
loops (Supplementary Fig. 2). Overall, the outer domain comprises
82% of the gp120 contact surface with b12, with the CD4-binding
loop forming a little over one-half of this surface.
Comparison of b12- and CD4-binding
Both CD4 and b12 bind primarily to the outer domain of gp120,
which is remarkably well preserved between unliganded, b12- and
CD4-bound states (Figs 2 and 3). Their entropies of interaction,
however, are very different, with CD4 inducing a 40–50 kcal mol21
change, and b12 inducing only a 6 kcal mol21 change10. This differ-
ence in conformational fixation of gp120 is seen in the divergent
atomic-mobility values of the domains (Fig. 3b).
The angles of approach of CD4 and b12 to gp120 are similar,
although not precisely the same (Fig. 3c). If the gp120 outer domains
of b12- and CD4-bound structures were superimposed to orient
equivalently b12 and CD4, about one-half of CD4 domain 1, which
makes all of the contacts with gp120, is not encompassed by the b12
Fab (despite the volume of the Fab variable domains being twice as
large as that of domain 1 of CD4). The projection of CD4 outside of
the angle of b12 approach suggests that the parameters that sterically
restrict b12 binding to the functional spike are not overly stringent.
The contact surfaces of CD4 and b12 on gp120 have considerable
overlap (Fig. 3a and Supplementary Fig. 4). Most of this overlap is on
the outer domain, where the CD4-binding loop is a central focus of
binding for both CD4 and b12. CD4 and b12, however, interact with
the CD4-binding loop quite differently (Fig. 3d). b12 uses all three of
its CDR heavy-chain loops to grasp virtually all surface-exposed por-
tions of the loop. In contrast, CD4 only binds to one side of the loop,
making anti-parallel hydrogen bonds between CD4- and gp120-
main-chain atoms.
The primary difference between b12 and CD4 interactions with
gp120 involves the conformationally mobile b20/21. For b12, these
interactions are peripheral to the binding surface, with alanine sub-
stitution of the primary b12 contact with b20/21 (at b12 residue
Asn 56) having little impact on overall b12 binding33. In contrast,
CD4 interactions with b20/21 form an integral part of the binding
surface, burying 160 A˚2 of surface area and forming a topologically
contiguous contact surface with the CD4-binding loop.
To delineate further the differences in binding between b12 and
CD4, we characterized binding interactions with an HIV-1 gp120
fragment, termed OD1 (ref. 34). This fragment comprises residues
252–482 and encompasses the entire outer domain including V3 as
well as the b20/21 excursion. Binding of b12 to OD1 showed nearly
identical rates of association compared to binding of b12 to HXBc2
core gp120, although the dissociation rate was about 15-fold more
rapid (Supplementary Fig. 5). We were unable to detect binding of
CD4 to OD1 (Supplementary Fig. 5). Because CD4 demonstrated
virtually no change in on-rate when tested on conformationally sta-
bilized gp120 molecules, we turned to a dodecameric variant of CD4
(D1D2-Igatp (ref. 35)), as avidity from multivalent binding provides
an effective means by which to reduce off-rate. We observed that
D1D2-Igatp binds with virtually identical rates of association to both
OD1 and core gp120 (Supplementary Fig. 5).
The results suggest the following series of molecular interactions
for b12 and CD4 binding to gp120 (Supplementary Fig. 6). Initial
contact by CD4 occurs with the structurally invariant outer domain,
to a surface constitutively exposed on the envelope spike. In primary
isolates, which are generally resistant to neutralization by soluble
CD4, this interaction is not stable and CD4 readily ‘falls off’.
However, at the cell surface (or with dodecameric CD4), multiple
CD4 molecules can bind simultaneously to the viral spike and use
avidity to enhance stability. The avidity-enhanced outer domain–
CD4 complex provides a receptive contact surface for the bridging
sheet. A highly coordinated rearrangement of the inner domain
allows for formation of the bridging sheet, which welds CD4 into
place.
b12-bound CD4-boundUnliganded SIV
Inner
domain
Inner
domain
Inner
domain
Outer
domain
Outer
domain
Outer domain:
Proximal
barrel
Barrel–barrel
juncture
Distal
barrel
Bridging
sheet
Figure 2 | Conformational states of gp120. The unliganded, b12- and CD4-
bound conformations of gp120 are depicted, with polypeptide in ribbon
representation and disordered regions as dashed lines. Inner domains are
grey, outer domains are red and regions that in the CD4-bound state
correspond to the bridging sheet are blue. Both b12- and CD4-bound
conformations are of the Ds12 F123 variant of HIV-1, whereas the
unliganded structure is of simian immunodeficiency virus (SIV).
Comparison of these three gp120 conformations highlights not only the
structural plasticity of the inner domain and bridging sheet, but also the
conformational stability of the outer domain.
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Contact by b12 occurs at the same constitutively exposed surface
initially recognized by CD4. However, b12 is able to latch onto this
outer domain surface with high affinity, without additional gp120
conformational change. This absence of conformational constraint
allows b12 to bind and neutralize primary isolates that otherwise
would be protected by conformational masking. In this manner,
b12 uses the functionally conserved initial contact site for CD4 on
gp120 to neutralize effectively HIV-1 (Fig. 4).
A site of HIV-1 vulnerability
Wedged between the glycan-shielded silent face and the conforma-
tionally flexible inner domain/bridging sheet, with its projecting vari-
able loops, the identified site is recessed, although it must be accessible
to a molecule as large as CD4 to serve its function. Otherwise, its size
and reactive loops make it suitable for recognition by antibody. Recent
serological analysis of long-term non-progressors attributes the broad
and potent neutralizing properties of some of these sera to antibodies
directed against this site36. The potential of receptor-binding-site anti-
bodies to effect broad neutralization has been recognized since the first
viral structures revealed conserved sites of receptor binding37,38. Here
we show how an unanticipated requirement for the maintenance of a
substantial receptor on-rate allows b12 to access and disable this most
difficult of targets, the highly protected HIV-1 Env.
METHODS
Structure-based stabilization of gp120 in its CD4-bound conformation.
Cavity-altering substitutions were identified by examination of highly conserved
residues that bordered interdomain cavities, whereas all Cb2Cb distances
between 3–7 A˚ were examined to identify potential stabilizing disulphides. A
high-throughput expression system, coupling transient expression with swain-
sonine, endoglycosidase H and concanavalin A, was devised from related pro-
cedures39 to produce gp120 suitable for crystallization. Briefly, codon-optimized
variants were constructed in the context of core gp120 (HXBc2) and expressed
transiently in 293 cells under control of the CMV/R promoter40. Swainsonine
(20 mg l21; Biomol) was added to the cell-culture medium 2 h before DNA
transfection, and supernatants were collected after 48 and 96 h. Secreted gp120
molecules were purified by 17b-affinity chromatography and deglycosylated
with endoglycosidase H (Endo Hf; New England Biolab) at pH 5.9, 37 uC, with
gp120 containing residual uncleaved glycan moieties removed by passage over
concanavalin A Sepharose (Sigma-Aldrich). Ternary complexes of deglycosy-
Functionally conserved
and antibody accessible
Conformationally
mobile
Antigenically
variable
Figure 4 | Structural definition of a conformationally invariant, antibody-
accessible portion of the CD4-binding site. The b12- and CD4-bound
conformations of gp120 are shown in ribbon representation, after
superposition of outer domains (red). A semitransparent molecular surface
shows the contact surfaces of b12 (green) and CD4 (yellow). Subsets of these
surfaces, corresponding to regions of conformational flexibility (for
example, of the inner domain (grey) or bridging sheet (blue)), are delineated,
as are regions of b12 contact outside of the conserved CD4-binding site. As
can be seen, functional analysis serves to transcend the particulars of b12
binding, whereas antibody defines accessibility. Although we have formally
shown only the b12 contact surface to be accessible in the context of a
functional viral spike, the highly effective neutralization of D1D2-Igatp and
the kinetics of its association with both core and OD1 variants of gp120
suggest that the CD4-binding surface on the outer domain is accessible.
a
b
c
d
b12-bound CD4-bound
b12 CD4
CD4-
binding
loop
Fixed Flexible
Tyr 53 Phe 43
90º
180º
Figure 3 | b12 and CD4 recognition of gp120. The orientation of gp120 in
a and b is the same as in Fig. 2, with c and d rotated about a horizontal axis by
90u and 180u, respectively. a, Molecular surface of gp120 in red, with the b12-
contact surface in green (left) and the CD4-contact surface in yellow (right).
b, Ribbon diagram of the b12- and CD4-bound gp120 coloured according to
the atomic mobility of the polypeptide, with white for fixed and red for
flexible. In the b12-induced conformation, only the outer domain is fixed by
interaction with antibody, with the average atomic mobility of the outer
domain about one-half that of the inner domain. By contrast, CD4 fixes the
entire core, resulting in outer and inner domains of similar overall atomic
mobility. c, Comparison of b12 and CD4 angles of attachment. The
polypeptide chains are depicted in ribbon representation, and coloured
according to Fig. 1, with CD4 in yellow. The similarity in angle of attachment
as well as the binding focus of b12 on the outer domain (red) are evident in
this orientation. d, The CD4-binding loop of gp120 (purple) is shown with
b12 (left) and CD4 (right). There are parallels between several key CD4
contact residues and those of b12. For example, Phe 43 of CD4 (shown in
stick model) inserts into a critical juncture at the nexus of the inner, outer
and bridging sheet regions of gp120, whereas Tyr 53 of b12 (also shown in
stick model) inserts at a similar position, although displaced by ,3 A˚.
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lated core gp120, d1d2 of CD4 and 17b Fab were prepared as described prev-
iously41, with P2221 crystals grown (Supplementary Table 1) around conditions
identified for the Drosophila-produced wild-type core18. Because crystals were
small (rods, typical diameter 40 mm) and subject to high radiation dosages dur-
ing data collection, difference Fourier maps comparing the initial and final
swatches of data were inspected to identify radiation-induced disulphide break-
age42, and the refined models (Supplementary Table 1) adjusted to reflect the
initial, radiation-damage-free structure.
Surface-plasmon resonance. A Biacore 3000 surface-plasmon resonance
spectrometer was used to measure kinetic constants (see Supplementary Table
4 and Supplementary Fig. 5 for details).
Isothermal titration calorimetry (ITC). Wild-type core and variant gp120
molecules were dialysed in PBS buffer and titrated with d1d2 of CD4 on a
MicroCal VP-ITC at 37 uC. Resultant data were examined using Origin software
(MicroCal).
Structural determination of a b12–gp120 complex. The antigen-binding frag-
ment (Fab) of b12 was produced by papain digestion, and purified with
Superdex S200 chromatography (0.35 M NaCl, 2.5 mM Tris pH 7.1, 0.02%
NaN3). The Fab peak was pooled and mixed with deglycosylated gp120, which
was produced by transient transfection as described above, and the resultant
complexes purified by S200 chromatography. Crystals of Fab b12 and a two-
disulphide variant (Ds12 F123) were grown by mixing 0.5ml of complex
(4 mg ml21) in S200 buffer with 0.5ml of droplet mix (10.5% PEG 8,000,
0.2 M glycine, 105 mM Mg-acetate, 52.5 mM Na-cacodylate pH 6.5) and equi-
librating in hanging droplets over reservoirs (droplet mix without glycine) at
20 uC. Hexagonal bi-pyramids (200 mm in length by 90 mm in diameter) were
crosslinked43, transferred to 15% PEG 8,000, 150 mM Mg-acetate, 100 mM Na-
cacodylate pH 6.5, 30% ethylene glycol, 2.5% 2R,3R-butandiol, 2.5% trehalose,
and flash-frozen in a nitrogen-cryostat stream. Data were collected at 100 K and
processed with HKL2000 (ref. 44). Molecular replacement (AMoRe45) identified
a 5.2s peak (15–3 A˚ data) for the Fab portion (chains H and L) of the b12 IgG
(Protein Data Bank 1HZH)29, and phases from the rigid-body refined molecule
allowed unambiguous placement of the outer domain in Fo2 Fc density. Iterative
model building (XtalView46), combined with refinement (CNS47, Refmac48), were
used to define the remaining ordered parts of gp120.
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